Degenerative Disc Disease - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Degenerative Disc Disease - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Degenerative Disc Disease - Pipeline Review, H1 2015', provides an overview of the Degenerative Disc Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Degenerative Disc Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Degenerative Disc Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Degenerative Disc Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Degenerative Disc Disease Overview 8
Therapeutics Development 9
Pipeline Products for Degenerative Disc Disease - Overview 9
Pipeline Products for Degenerative Disc Disease - Comparative Analysis 10
Degenerative Disc Disease - Therapeutics under Development by Companies 11
Degenerative Disc Disease - Therapeutics under Investigation by Universities/Institutes 13
Degenerative Disc Disease - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Degenerative Disc Disease - Products under Development by Companies 17
Degenerative Disc Disease - Products under Investigation by Universities/Institutes 18
Degenerative Disc Disease - Companies Involved in Therapeutics Development 19
AnGes MG, Inc. 19
Biogenomics Limited 20
Bioheart, Inc. 21
BioRestorative Therapies, Inc. 22
Bone Therapeutics SA 23
DePuy Spine, Inc. 24
Discgenics, Inc 25
ISTO Technologies, Inc. 26
K-Stemcell Co., Ltd. 27
Mesoblast Limited 28
TissueGene, Inc. 29
Yuhan Corporation 30
Degenerative Disc Disease - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
AdipoCell - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ALLOB - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
brtxDISC - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CHND-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
dibotermin alfa - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
MPC-25Osteo - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NuQu Cell-Based Therapy - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Poly N-Acetyl Glucosamine Hydrogel - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Recombinant Protein for Degenerative Disc Disease - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
S-414114 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Stem Cell Therapy - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
TG-D - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
YH-14618 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Degenerative Disc Disease - Recent Pipeline Updates 62
Degenerative Disc Disease - Product Development Milestones 67
Featured News & Press Releases 67
Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA 67
Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA 67
Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease 67
Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion 68
Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease 69
Mar 07, 2014: Stem Cell Transplant Shows "Landmark" Promise for Treatment of Degenerative Disc Disease 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables
Number of Products under Development for Degenerative Disc Disease, H1 2015 9
Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Degenerative Disc Disease - Pipeline by AnGes MG, Inc., H1 2015 19
Degenerative Disc Disease - Pipeline by Biogenomics Limited, H1 2015 20
Degenerative Disc Disease - Pipeline by Bioheart, Inc., H1 2015 21
Degenerative Disc Disease - Pipeline by BioRestorative Therapies, Inc., H1 2015 22
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1 2015 23
Degenerative Disc Disease - Pipeline by DePuy Spine, Inc., H1 2015 24
Degenerative Disc Disease - Pipeline by Discgenics, Inc, H1 2015 25
Degenerative Disc Disease - Pipeline by ISTO Technologies, Inc., H1 2015 26
Degenerative Disc Disease - Pipeline by K-Stemcell Co., Ltd., H1 2015 27
Degenerative Disc Disease - Pipeline by Mesoblast Limited, H1 2015 28
Degenerative Disc Disease - Pipeline by TissueGene, Inc., H1 2015 29
Degenerative Disc Disease - Pipeline by Yuhan Corporation, H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Degenerative Disc Disease Therapeutics - Recent Pipeline Updates, H1 2015 62